Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
Akebia Therapeutics has entered a multi-year commercial supply agreement with a leading dialysis organization to provide access to its drug Vafseo® (vadadustat) for dialysis patients. This strategic move could enhance Akebia’s market presence in the dialysis segment, offering potential growth opportunities.
Learn more about AKBA stock on TipRanks’ Stock Analysis page.